{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:37:07Z","timestamp":1790318227724,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajem.2022.11.023","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T02:33:43Z","timestamp":1668738823000},"page":"74-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage"],"prefix":"10.1016","volume":"64","author":[{"given":"Elly S.","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2022.11.023_bb0005","series-title":"Portola Pharmaceuticals, Inc., South San Francisco, CA","author":"Andexxa\u00ae [Package Insert]","year":"2018"},{"key":"10.1016\/j.ajem.2022.11.023_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.ajem.2022.11.023_bb0015","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2022.11.023_bb0020","doi-asserted-by":"crossref","first-page":"00","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2022.11.023_bb0025","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2022.11.023_bb0030","series-title":"ClinicalTrials.gov Identifier NCT03661528","article-title":"Trial of andexanet in ICH patients receiving an oral FXa inhibitor","author":"Alexion Pharmaceuticals","year":"2022"},{"issue":"8","key":"10.1016\/j.ajem.2022.11.023_bb0035","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/01.STR.27.8.1304","article-title":"The ABCs of measuring intracerebral hemorrhage volumes","volume":"27","author":"Kothari","year":"1996","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ajem.2022.11.023_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.ccm.0000728348.25608.90","article-title":"Andexanet alfa versus 4-factor PCC for reversal of intracranial hemorrhage associated with factor Xa","volume":"49","author":"Semon","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ajem.2022.11.023_bb0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.ajem.2022.11.023_bb0050","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ajem.2022.11.023_bb0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11239-021-02495-3","article-title":"Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage","volume":"53","author":"Vestal","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ajem.2022.11.023_bb0060","first-page":"195","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","author":"Giovino","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ajem.2022.11.023_bb0065","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2022.11.023_bb0070","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ajem.2022.11.023_bb0075","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- and apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ajem.2022.11.023_bb0080","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ajem.2022.11.023_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2020","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ajem.2022.11.023_bb0090","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajem.2019.12.008","article-title":"Real-world utilization of andexanet alfa","volume":"38","author":"Brown","year":"2020","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2022.11.023_bb0095","series-title":"CSL Behring LLC, Kankakee, IL","author":"KCentra\u00ae [Package Insert]","year":"2020"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675722007288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675722007288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:04:10Z","timestamp":1760025850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675722007288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":19,"alternative-id":["S0735675722007288"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2022.11.023","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2022.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}